» Articles » PMID: 34104471

Relapse Recovery in Multiple Sclerosis: Effect of Treatment and Contribution to Long-term Disability

Overview
Date 2021 Jun 9
PMID 34104471
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor.

Objective: To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-year disability and MRI outcomes.

Methods: Relapse recovery was retrospectively assessed in 360 patients with MS using the return of the Expanded Disability Status Scale (EDSS), Functional System Scale and neurologic signs to baseline at least 6 months after onset. Univariate and multivariable models were used to associate recovery with demographic and clinical factors and predict 10-year outcomes.

Results: Recovery from relapses in the first 3 years was better in patients who were younger, on disease-modifying treatment, with a longer disease duration and without bowel or bladder symptoms. For every incomplete recovery, 10-year EDSS increased by 0.6 and 10-year timed 25-foot walk increased by 0.5 s. These outcomes were also higher with older age and higher baseline BMI. Ten-year MRI brain atrophy was associated only with older age, and MRI lesion volume was only associated with smoking.

Conclusions: Early initiation of disease-modifying treatment in MS was associated with improved relapse recovery, which in turn prevented long-term disability.

Citing Articles

Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid-refractory multiple sclerosis relapses.

Vardakas I, Dorst J, Huss A, Mayer B, Fangerau T, Taranu D Eur J Neurol. 2024; 31(8):e16323.

PMID: 38700322 PMC: 11235822. DOI: 10.1111/ene.16323.


Multiple sclerosis lesions that impair memory map to a connected memory circuit.

Kletenik I, Cohen A, Glanz B, Ferguson M, Tauhid S, Li J J Neurol. 2023; 270(11):5211-5222.

PMID: 37532802 PMC: 10592111. DOI: 10.1007/s00415-023-11907-8.


Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD.

Fadda G, Flanagan E, Cacciaguerra L, Jitprapaikulsan J, Solla P, Zara P Front Neurol. 2022; 13:1011579.

PMID: 36419536 PMC: 9676369. DOI: 10.3389/fneur.2022.1011579.


Neurodegeneration in multiple sclerosis.

Mey G, Mahajan K, DeSilva T WIREs Mech Dis. 2022; 15(1):e1583.

PMID: 35948371 PMC: 9839517. DOI: 10.1002/wsbm.1583.


Retinal Layer Thinning After Optic Neuritis Is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis.

Bsteh G, Krajnc N, Riedl K, Altmann P, Kornek B, Leutmezer F Neurology. 2022; 99(16):e1803-e1812.

PMID: 35918172 PMC: 9620804. DOI: 10.1212/WNL.0000000000200970.


References
1.
Leone M, Bonissoni S, Collimedaglia L, Tesser F, Calzoni S, Stecco A . Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study. Mult Scler. 2008; 14(4):485-93. DOI: 10.1177/1352458507084650. View

2.
Chitnis T, Gonzalez C, Healy B, Saxena S, Rosso M, Barro C . Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2018; 5(12):1478-1491. PMC: 6292183. DOI: 10.1002/acn3.638. View

3.
Battaglini M, Gentile G, Luchetti L, Giorgio A, Vrenken H, Barkhof F . Lifespan normative data on rates of brain volume changes. Neurobiol Aging. 2019; 81:30-37. DOI: 10.1016/j.neurobiolaging.2019.05.010. View

4.
Kantarci O, Zeydan B, Atkinson E, Conway B, Castrillo-Viguera C, Rodriguez M . Relapse recovery: The forgotten variable in multiple sclerosis clinical trials. Neurol Neuroimmunol Neuroinflamm. 2019; 7(2). PMC: 6943367. DOI: 10.1212/NXI.0000000000000653. View

5.
Rosso M, Chitnis T . Association Between Cigarette Smoking and Multiple Sclerosis: A Review. JAMA Neurol. 2019; 77(2):245-253. DOI: 10.1001/jamaneurol.2019.4271. View